<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>12(31)</volume><submitter>Jorgensen AM</submitter><funding>Nachwuchsförderung der Universität Innsbruck/Support Program for Junior Scientists at the University of Innsbruck</funding><pubmed_abstract>Alternative methods to hydrophobic ion pairing for the formation of lipophilic complexes of peptide drugs to incorporate them in lipid-based nanocarriers such as self-emulsifying drug delivery systems (SEDDS) for oral administration are highly on demand. Such an alternative might be reverse micelles. Within this study, SEDDS containing dry reverse micelles (dRMs&lt;sub>PMB&lt;/sub> ) formed with an anionic (sodium docusate; AOT), cationic (dimethyl-dioctadecyl-ammonium bromide; DODAB), amphoteric (soy lecithin; SL), or non-ionic (polysorbate 85; P85) surfactant loaded with the model peptide drug polymyxin B (PMB) are developed. They are characterized regarding size, payload, release kinetics, cellular uptake, and peptide activity. SEDDS exhibit sizes from 22.2 ± 1.7 (AOT-SEDDS-dRMs&lt;sub>PMB&lt;/sub> ) to 61.7 ± 3.2 nm (P85-SEDDS-dRMs&lt;sub>PMB&lt;/sub> ) with payloads up to 2% that are approximately sevenfold higher than those obtained via hydrophobic ion pairing. Within 6 h P85-SEDDS-dRMs&lt;sub>PMB&lt;/sub> and AOT-SEDDS-dRMs&lt;sub>PMB&lt;/sub> show no release of PMB in aqueous medium, whereas DODAB-SEDDS-dRMs&lt;sub>PMB&lt;/sub> and SL-SEDDS-dRMs&lt;sub>PMB&lt;/sub> show a sustained release. DODAB-SEDDS-dRMs&lt;sub>PMB&lt;/sub> improves uptake by Caco-2 cells most efficiently reaching even ≈100% within 4 h followed by AOT-SEDDS-dRMs&lt;sub>PMB&lt;/sub> with ≈20% and P85-/SL-SEDDS-dRMs&lt;sub>PMB&lt;/sub> with ≈5%. The peptide drug maintains its antimicrobial activity in all SEDDS-dRMs&lt;sub>PMB&lt;/sub> . According to these results, SEDDS containing dRMs might be a game changing strategy for oral peptide drug delivery.</pubmed_abstract><journal>Advanced healthcare materials</journal><pagination>e2302034</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11468804</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Self-Emulsifying Drug Delivery Systems (SEDDS) Containing Reverse Micelles: Advanced Oral Formulations for Therapeutic Peptides.</pubmed_title><pmcid>PMC11468804</pmcid><pubmed_authors>Jorgensen AM</pubmed_authors><pubmed_authors>Steinbring C</pubmed_authors><pubmed_authors>Schmid P</pubmed_authors><pubmed_authors>Stengel D</pubmed_authors><pubmed_authors>To D</pubmed_authors><pubmed_authors>Bernkop-Schnurch A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Self-Emulsifying Drug Delivery Systems (SEDDS) Containing Reverse Micelles: Advanced Oral Formulations for Therapeutic Peptides.</name><description>Alternative methods to hydrophobic ion pairing for the formation of lipophilic complexes of peptide drugs to incorporate them in lipid-based nanocarriers such as self-emulsifying drug delivery systems (SEDDS) for oral administration are highly on demand. Such an alternative might be reverse micelles. Within this study, SEDDS containing dry reverse micelles (dRMs&lt;sub>PMB&lt;/sub> ) formed with an anionic (sodium docusate; AOT), cationic (dimethyl-dioctadecyl-ammonium bromide; DODAB), amphoteric (soy lecithin; SL), or non-ionic (polysorbate 85; P85) surfactant loaded with the model peptide drug polymyxin B (PMB) are developed. They are characterized regarding size, payload, release kinetics, cellular uptake, and peptide activity. SEDDS exhibit sizes from 22.2 ± 1.7 (AOT-SEDDS-dRMs&lt;sub>PMB&lt;/sub> ) to 61.7 ± 3.2 nm (P85-SEDDS-dRMs&lt;sub>PMB&lt;/sub> ) with payloads up to 2% that are approximately sevenfold higher than those obtained via hydrophobic ion pairing. Within 6 h P85-SEDDS-dRMs&lt;sub>PMB&lt;/sub> and AOT-SEDDS-dRMs&lt;sub>PMB&lt;/sub> show no release of PMB in aqueous medium, whereas DODAB-SEDDS-dRMs&lt;sub>PMB&lt;/sub> and SL-SEDDS-dRMs&lt;sub>PMB&lt;/sub> show a sustained release. DODAB-SEDDS-dRMs&lt;sub>PMB&lt;/sub> improves uptake by Caco-2 cells most efficiently reaching even ≈100% within 4 h followed by AOT-SEDDS-dRMs&lt;sub>PMB&lt;/sub> with ≈20% and P85-/SL-SEDDS-dRMs&lt;sub>PMB&lt;/sub> with ≈5%. The peptide drug maintains its antimicrobial activity in all SEDDS-dRMs&lt;sub>PMB&lt;/sub> . According to these results, SEDDS containing dRMs might be a game changing strategy for oral peptide drug delivery.</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Dec</publication><modification>2025-04-04T13:54:52.149Z</modification><creation>2025-04-04T13:54:52.149Z</creation></dates><accession>S-EPMC11468804</accession><cross_references><pubmed>37696266</pubmed><doi>10.1002/adhm.202302034</doi></cross_references></HashMap>